Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tedisamil (Solvay).

N A Flores1

  • 1Imperial College School of Medicine, Academic Cardiology Unit, National Heart and Lung Institute Division, London, UK. n.flores@ic.ac.uk

Current Opinion in Investigational Drugs (London, England : 2000)
|August 31, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Divergence between respirometry and physicochemical methods in the fractionation of the chemical oxygen demand in municipal wastewater.

Water environment research : a research publication of the Water Environment Federation·2011
Same author

Changes in extracellular pH and myocardial ischaemia alter the cardiac effects of diadenosine tetraphosphate and pentaphosphate.

British journal of pharmacology·2001
Same author

Contribution of nitric oxide and prostanoids to the cardiac electrophysiological and coronary vasomotor effects of diadenosine polyphosphates.

The Journal of pharmacology and experimental therapeutics·2001
Same author

Coronary vasomotor and cardiac electrophysiologic effects of diadenosine polyphosphates and nonhydrolyzable analogs in the guinea pig.

Journal of cardiovascular pharmacology·2001
Same author

Investigation of mechanisms that mediate reactive hyperaemia in guinea-pig hearts: role of K(ATP) channels, adenosine, nitric oxide and prostaglandins.

British journal of pharmacology·2001
Same author

Products of the platelet release reaction influence cardiac electrophysiology independently of platelet-platelet interactions.

Platelets·2000
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Tedisamil, a potassium channel blocker, shows promise for treating atrial fibrillation. It effectively terminates and prevents atrial fibrillation in canine models without negatively impacting myocardial function.

Area of Science:

  • Pharmacology
  • Cardiology
  • Electrophysiology

Background:

  • Tedisamil is a novel potassium channel blocker investigated for cardiac conditions.
  • It is classified as a class III anti-arrhythmic agent.
  • Solvay is developing tedisamil, currently in Phase II trials for atrial fibrillation.

Purpose of the Study:

  • To evaluate the efficacy and safety of tedisamil in treating atrial fibrillation.
  • To investigate the electrophysiological effects of tedisamil on cardiac potassium channels.
  • To assess tedisamil's impact on myocardial function and hemodynamics.

Main Methods:

  • Preclinical studies in rat, rabbit, canine, and simian hearts.
  • Canine models of exercise-induced angina and induced atrial fibrillation.

Related Experiment Videos

  • Electrophysiological assessments of potassium channel activity and action potential duration.
  • Hemodynamic monitoring including diastolic arterial pressure.

    • Main Results:

    • Tedisamil demonstrated a marked prolongation of action potential by modulating potassium channels.
    • The drug rapidly terminated sustained atrial fibrillation and prevented its reinitiation in canine models.
    • Tedisamil exhibited bradycardic effects without negative inotropic effects, maintaining myocardial function in canine angina models.
    • Diastolic arterial pressure remained uninfluenced by tedisamil.

    Conclusions:

    • Tedisamil's class III antiarrhythmic effect is primarily due to potent blockade of the rapid component of the delayed rectifier potassium current.
    • Tedisamil shows significant potential for the treatment of atrial fibrillation.
    • The drug's favorable hemodynamic profile and lack of negative inotropic effects warrant further clinical investigation.